Goldman Sachs’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Goldman Sachs’s Portfolio BIVV Stock Details BIVV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-7,650	Closed	-$412K	–	6657
2017 Q4	$412K	Hold	7,650	–	–	﹤0.01%	4979
2017 Q3	$437K	Sell	7,650 -3,000	-28%	-$176K	﹤0.01%	5191
2017 Q2	$641K	Sell	10,650 -8,800	-45%	-$501K	﹤0.01%	4873
2017 Q1	$1.06M	Buy	+19,450	New	+$958K	﹤0.01%	4324

Other funds holding BIVV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

ACS

Archford Capital Strategies Swansea, Illinois $987M AUM 29.31% 1-Year Est. Return

Goldman Sachs's BIVV Position: Q1 2018 in Review

Goldman Sachs sold out of Bioverativ Inc. Common Stock (BIVV) in Q1 2018, closing a stake of 1,143,890 shares — an estimated $61.7M sold.

Goldman Sachs first reported a position in BIVV in Q1 2017 and held it in 4 quarters. The position peaked at $131M in Q3 2017. 2 funds tracked by Wall St. Rank hold BIVV as of Q1 2018.

Goldman Sachs reported no remaining Bioverativ Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
Goldman Sachs sold 1,143,890 Bioverativ Inc. Common Stock shares in Q1 2018, an estimated $61.7M.
Goldman Sachs first reported a position in Bioverativ Inc. Common Stock in Q1 2017 and held it in 4 quarters.
Goldman Sachs's Bioverativ Inc. Common Stock position peaked at $131M in Q3 2017.
2 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q1 2018.

Based on Goldman Sachs's 13F filing for Q1 2018, filed 15 May 2018.